|Jmol-3D images||Image 1
|Molar mass||437.51 g mol−1|
| (what is: / ?)
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
Aleglitazar is a peroxisome proliferator-activated receptor agonist (hence a PPAR modulator ) with affinity to PPARα and PPARγ, which was under development by Hoffmann–La Roche for the treatment of type II diabetes. It is no longer in phase III clinical trials.
- "Statement on a nonproprietary name adopted by the USAN Council: Aleglitazar". United States Adopted Names. American Medical Association. Retrieved 2008-08-17.
- "Roche halts diabetes drug trial in blow to pipeline". Roche. Retrieved 2013-07-10.
|This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.|